DMTK - PAVmed: A True Game-Changer For Medical Device Innovation

• PAVmed's main commercial-stage product, EsoCheck/EsoGuard, is a life-saving product addressing a $25bil market and is supported by Exact Sciences founder Stanley Lapidus.
• PAVmed's second commercial-stage product, CarpX, is a minimally invasive tool to conduct carpel tunnel surgery and can save patients weeks or months of recovery time.
• PAVmed management is continuously finding new innovative products to add to their pipeline, which can be seen from the recent acquisition of a majority stake in Oncodisc.
• Based on the valuations of other disruptive healthcare companies, I think PAVmed's Lucid stake alone should be worth far more than the current market valuation.

For further details see: